Announcements Trials
Browse Landscape

Phase

Phase 2 5Phase 3 2Phase 4 1

Status

Completed 8Recruiting 6Unknown 2Terminated 2Withdrawn 1Not yet recruiting 1Active not recruiting 1

Sponsor Class

OTHER 2

Study Type

Interventional 2

Sponsor

Cancer Type

Other solid neoplasm 1Genitourinary 1

Conditions

Vomiting 1Testicular Neoplasms 1Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy 1Nausea 1

Interventions

Cisplatin 130Radiotherapy 94Carboplatin 85Paclitaxel 78Fluorouracil 78Cyclophosphamide 77Gemcitabine 72Capecitabine 66Docetaxel 65Doxorubicin 60Oxaliplatin 59Etoposide 57Leucovorin 49Vincristine 47Chemotherapy, Adjuvant 42Cytarabine 38Dexamethasone 35Drug Therapy 33Bevacizumab 30Epirubicin 29Neoadjuvant Therapy 28Pemetrexed 27Tamoxifen 25Prednisone 24Irinotecan 24Rituximab 21Methotrexate 21Radiotherapy, Intensity-Modulated 19apatinib 18Vinorelbine 18

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

2 trials
RecentStart dateEnrollment
Phase 3 × Unknown × Olanzapine × Clear all
NCT05244577 2023-02-06

Olanzapine Combined With Fosaprepitant, Ondansetron, and Dexamethasone for Preventing Nausea and Vomiting in Patients With Testicular Cancer

Sun Yat-sen University

Phase 3 Unknown
75 enrolled
Genitourinary

Nausea, Testicular Neoplasms, Vomiting

NCT04536558 2020-09-02

OFFER

Sun Yat-sen University

Phase 3 Unknown
352 enrolled
Other solid neoplasm

Solid Tumor Patients Receiving High Emetic Risk Multi-day Chemotherapy

Data powered by HemOnc (CC BY 4.0) Colophon âš¡